OLMA
Olema Pharmaceuticals, Inc.
$7.94
+0.02
(+0.25%)
Mkt Cap
693.54M
Volume
818,546
52W Range
6.65-36.26
Sector
Healthcare
Beta
2.01
EPS (TTM)
-2.12 USD
P/E Ratio
-13.37
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.45M) | (129.47M) | (96.66M) | (104.79M) | (71.10M) | (22.12M) | (4.32M) | (2.20M) |
| EPS | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 | -0.11 | -0.16 |
| Free Cash Flow | (146.72M) | (104.51M) | (83.73M) | (82.43M) | (52.27M) | (19.92M) | (3.08M) | (2.18M) |
| FCF / Share | -1.69 | -1.78 | -1.85 | -2.06 | -1.32 | -0.51 | -0.08 | -0.15 |
| Operating CF | (146.72M) | (104.35M) | (83.73M) | (82.06M) | (50.69M) | (19.87M) | (3.08M) | (2.18M) |
| Total Assets | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M | 342.72M | 132,000 | 3.27M |
| Total Debt | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M | 0 | 0 | 0 |
| Cash & Equiv | 48.30M | 139.48M | 68.54M | 23.70M | 13.81M | 338.55M | 68,000 | 3.15M |
| Book Value | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M | 338.14M | (10.59M) | (6.28M) |
| Return on Equity | -0.34 | -0.32 | -0.38 | -0.53 | -0.25 | -0.07 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.20M) | (53.09M) | (46.06M) | (42.22M) | (43.78M) | (30.39M) | (33.57M) | (34.55M) | (30.38M) | (30.97M) | (26.77M) | (21.50M) |
| EPS | -0.61 | -0.52 | -0.50 | -0.49 | -0.51 | -0.36 | -0.57 | -0.60 | -0.54 | -0.56 | -0.49 | -0.48 |
| Free Cash Flow | (45.90M) | (45.99M) | (38.33M) | (34.53M) | (29.88M) | (43.98M) | (26.28M) | (27.02M) | (27.56M) | (23.65M) | (18.48M) | (22.74M) |
| FCF / Share | -0.44 | -0.45 | -0.42 | -0.40 | -0.35 | -0.51 | -0.45 | -0.47 | -0.49 | -0.43 | -0.34 | -0.51 |
| Operating CF | (45.90M) | (45.99M) | (38.33M) | (34.53M) | (29.88M) | (43.98M) | (26.28M) | (27.02M) | (27.55M) | (23.50M) | (18.48M) | (22.74M) |
| Total Assets | 486.58M | 530.64M | 533.43M | 352.45M | 382.00M | 409.64M | 450.98M | 230.17M | 254.56M | 263.69M | 276.94M | 292.80M |
| Total Debt | 660,000 | 956,000 | 1.19M | 4.48M | 4.75M | 1.15M | 1.43M | 1.70M | 1.96M | 2.21M | 2.42M | 2.62M |
| Cash & Equiv | 48.60M | 52.55M | 48.30M | 35.26M | 52.47M | 50.64M | 139.48M | 35.89M | 16.89M | 33.72M | 68.54M | 117.41M |
| Book Value | 430.56M | 480.48M | 478.56M | 307.49M | 345.24M | 383.45M | 408.96M | 198.91M | 227.16M | 236.32M | 253.90M | 275.13M |
| Return on Equity | -0.15 | -0.11 | -0.10 | -0.14 | -0.13 | -0.08 | -0.08 | -0.17 | -0.13 | -0.13 | -0.11 | -0.08 |
OLMA News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)